RECRUITINGOBSERVATIONAL
The Australia and New Zealand Multicentre Upper Gastrointestinal Endoscopic Tissue Resection Study
About This Trial
To determine the long term outcomes of Endoscopic Submucosal Dissection (ESD), Endoscopic Full Thickness Resection (EFTR) and Submucosal-Tunnelling Endoscopic Resection (STER) for upper gastrointestinal neoplastic lesions
Who May Be Eligible (Plain English)
Who May Qualify:
- UGI neoplastic lesions \> 10mm
- Lesions for ESD limited to the mucosal and/or submucosal layer OR
- Lesions for EFTR limited to the muscularis propria layer OR
- Lesions for STER limited to the submucosal and/or muscularis propria layer
- Aged 18 years or older
Who Should NOT Join This Trial:
- Age less than 18
- Unable to give willing to sign a consent form
- Pregnant or lactating patients
- Patients with bleeding diathesis or who cannot discontinue ADP blockers (e.g. clopidogrel, prasugrel) or antithrombotics (e.g. warfarin, dabigatran) periprocedurally
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* UGI neoplastic lesions \> 10mm
* Lesions for ESD limited to the mucosal and/or submucosal layer OR
* Lesions for EFTR limited to the muscularis propria layer OR
* Lesions for STER limited to the submucosal and/or muscularis propria layer
* Aged 18 years or older
Exclusion Criteria:
* Age less than 18
* Unable to give informed consent
* Pregnant or lactating patients
* Patients with bleeding diathesis or who cannot discontinue ADP blockers (e.g. clopidogrel, prasugrel) or antithrombotics (e.g. warfarin, dabigatran) periprocedurally
Locations (1)
Westmead Hospital
Sydney, New South Wales, Australia